Daewoong Pharma
KRX:069620
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
100 600
161 100
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Daewoong Pharma stock under the Base Case scenario is 213 530.48 KRW. Compared to the current market price of 129 100 KRW, Daewoong Pharma is Undervalued by 40%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Daewoong Pharma
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Daewoong Pharma cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Daewoong Pharma
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Daewoong Pharma
Balance Sheet Decomposition
Daewoong Pharma
Current Assets | 574.8B |
Cash & Short-Term Investments | 137.7B |
Receivables | 178B |
Other Current Assets | 259.2B |
Non-Current Assets | 1.2T |
Long-Term Investments | 273.9B |
PP&E | 521.9B |
Intangibles | 297.5B |
Other Non-Current Assets | 102.2B |
Current Liabilities | 667.1B |
Accounts Payable | 101.1B |
Accrued Liabilities | 26.6B |
Short-Term Debt | 167.4B |
Other Current Liabilities | 372B |
Non-Current Liabilities | 335.9B |
Long-Term Debt | 66.9B |
Other Non-Current Liabilities | 268.9B |
Earnings Waterfall
Daewoong Pharma
Revenue
|
1.4T
KRW
|
Cost of Revenue
|
-691B
KRW
|
Gross Profit
|
725.7B
KRW
|
Operating Expenses
|
-587.7B
KRW
|
Operating Income
|
137.9B
KRW
|
Other Expenses
|
-34.4B
KRW
|
Net Income
|
103.6B
KRW
|
Free Cash Flow Analysis
Daewoong Pharma
KRW | |
Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
Daewoong Pharma's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Daewoong Pharma's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Daewoong Pharma's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Daewoong Pharma's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Daewoong Pharma
According to Wall Street analysts, the average 1-year price target for Daewoong Pharma is 195 257.14 KRW with a low forecast of 161 600 KRW and a high forecast of 231 000 KRW.
Dividends
Current shareholder yield for Daewoong Pharma is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Daewoong Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-11-01. The firm's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The firm distributes its products in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Daewoong Pharma stock under the Base Case scenario is 213 530.48 KRW.
Compared to the current market price of 129 100 KRW, Daewoong Pharma is Undervalued by 40%.